Latest news with #EtonPharmaceuticals
Yahoo
27-06-2025
- Business
- Yahoo
Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes
DEER PARK, Ill., June 27, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ('Eton' or the 'Company') (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will be added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes, effective after the U.S. market closes on June 27, as part of the 2025 Russell Indexes reconstitution. 'Eton's addition to the Russell 2000 and Russell 3000 Indexes is a significant milestone and recognizes the tremendous shareholder value we've generated over the past twelve months. We're proud to be part of these important market performance benchmarks and look forward to expanding our visibility among investors as we continue bringing much needed treatments to patients with ultra-rare conditions,' said Sean Brynjelsen, CEO of Eton Pharmaceuticals. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. For more information on the Russell 3000® Index and the Russell indexes reconstitution, visit the 'Russell Reconstitution' section on the FTSE Russell website. About Eton Pharmaceuticals Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has eight commercial rare disease products: KHINDIVI®, INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has five additional product candidates in late-stage development: ET-600, Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton's business strategy, Eton's plans to develop and commercialize its product candidates, the safety and efficacy of Eton's product candidates, Eton's plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton's product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as 'believes,' 'anticipates,' 'plans,' 'expects,' 'intends,' 'will,' 'goal,' 'potential' and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton's development programs and financial position are described in additional detail in Eton's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor Relations:Lisa M. Wilson, In-Site Communications, Inc.T: 212-452-2793E: lwilson@ Source: Eton Pharmaceuticals.
Yahoo
17-06-2025
- Business
- Yahoo
Insiders Back These 3 High Growth Companies
As the United States stock market navigates the complexities of geopolitical tensions and fluctuating oil prices, investors are closely monitoring economic indicators and Federal Reserve decisions for signs of stability. In such uncertain times, companies with high insider ownership can be particularly appealing, as they often signal strong internal confidence in growth potential amidst broader market volatility. Name Insider Ownership Earnings Growth Super Micro Computer (SMCI) 16.2% 39.1% QT Imaging Holdings (QTIH) 26.7% 84.5% Prairie Operating (PROP) 34.5% 75.7% FTC Solar (FTCI) 27.7% 62.5% Enovix (ENVX) 12.1% 58.4% Eagle Financial Services (EFSI) 15.9% 82.8% Credo Technology Group Holding (CRDO) 12.1% 45% Atour Lifestyle Holdings (ATAT) 22.6% 24.1% Astera Labs (ALAB) 14.8% 44.4% Antalpha Platform Holding (ANTA) 18.4% 40.2% Click here to see the full list of 190 stocks from our Fast Growing US Companies With High Insider Ownership screener. Below we spotlight a couple of our favorites from our exclusive screener. Simply Wall St Growth Rating: ★★★★★☆ Overview: Eton Pharmaceuticals, Inc. is a pharmaceutical company that develops and commercializes treatments for rare diseases, with a market cap of $383.49 million. Operations: The company generates revenue of $48.33 million from its segment focused on developing and commercializing prescription drug products. Insider Ownership: 11.9% Eton Pharmaceuticals has recently achieved FDA approval for KHINDIVI, a unique oral solution for pediatric adrenocortical insufficiency, enhancing its product portfolio alongside ALKINDI SPRINKLE. While the company reported a net loss of US$1.57 million in Q1 2025, revenue surged to US$17.28 million from the previous year. Despite significant insider selling over the past quarter, Eton's revenue is forecasted to grow substantially faster than the market average at 28.5% annually, with expectations of profitability within three years. Click to explore a detailed breakdown of our findings in Eton Pharmaceuticals' earnings growth report. In light of our recent valuation report, it seems possible that Eton Pharmaceuticals is trading behind its estimated value. Simply Wall St Growth Rating: ★★★★★☆ Overview: MNTN, Inc. is a performance TV software company offering advertising services in the United States with a market cap of $1.42 billion. Operations: The company's revenue is primarily derived from its Internet Software & Services segment, totaling $246.27 million. Insider Ownership: 12.5% MNTN, Inc. recently completed a US$187.2 million IPO and filed a shelf registration for US$699.38 million, signaling expansion plans. Despite highly illiquid shares, the company is trading at 53.4% below its estimated fair value and is forecasted to achieve profitability within three years with earnings growth of 74.52% annually, outpacing market averages. Although insider activity shows significant selling recently, MNTN's revenue growth of 14.7% per year exceeds the broader U.S. market rate of 8.7%. Delve into the full analysis future growth report here for a deeper understanding of MNTN. Our valuation report here indicates MNTN may be overvalued. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Workiva Inc. provides cloud-based reporting solutions globally and has a market cap of approximately $3.66 billion. Operations: The company's revenue is primarily derived from its data processing segment, which generated $769.29 million. Insider Ownership: 10.6% Workiva's recent appointment of Astha Malik to its board underscores its focus on strategic growth, leveraging her extensive experience in scaling SaaS operations. The company is expected to achieve profitability within three years, with projected annual earnings growth of 80.09%, surpassing market averages. While insider buying has been more substantial than selling recently, Workiva's revenue is forecasted to grow at 15.2% annually, outpacing the broader U.S. market but below the 20% threshold for high growth expectations. Unlock comprehensive insights into our analysis of Workiva stock in this growth report. Upon reviewing our latest valuation report, Workiva's share price might be too pessimistic. Click through to start exploring the rest of the 187 Fast Growing US Companies With High Insider Ownership now. Looking For Alternative Opportunities? The end of cancer? These 23 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include ETON MNTN and WK. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
29-05-2025
- Business
- Yahoo
Eton Pharmaceuticals, Inc. (ETON) Launches Game-Changer for Adrenal Insufficiency
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has received FDA approval for KHINDIVI, the first and only hydrocortisone oral solution available in the United States, marking a major milestone for pediatric care. Designed for children aged five and older with adrenocortical insufficiency, a rare disorder where the adrenal glands do not produce enough cortisol, KHINDIVI offers a 1mg/ml ready-to-use liquid formulation. This eliminates the need for splitting or crushing tablets and allows for precise, incremental dosing tailored to each child's needs. The solution does not require refrigeration, mixing, or shaking, making it especially suitable for patients who have trouble swallowing pills or need administration via a gastric tube. A clinical researcher in a lab examining a new biopharmaceutical product. Eton Pharmaceuticals, Inc. (NASDAQ:ETON) expects to launch KHINDIVI commercially the week of June 2, with combined peak sales from KHINDIVI and its companion product, ALKINDI SPRINKLE, projected to exceed $50 million annually. The medication will be distributed exclusively through Anovo, a specialty pharmacy, and supported by the Eton Cares Program, which provides prescription fulfillment, insurance support, educational resources, and co-pay assistance. This FDA approval is seen as a significant advancement for families and clinicians managing pediatric adrenal insufficiency, offering a new, accurate, and accessible treatment option. While we acknowledge the potential of ETON to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ETON and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
29-05-2025
- Business
- Business Insider
Eton Pharmaceuticals announces FDA approval for KHINDIVI
Eton Pharmaceuticals (ETON) 'announced the U.S. Food and Drug Administration approval of a New Drug Application for KHINDIVI Oral Solution as a replacement therapy in pediatric patients five years of age and older with adrenocortical insufficiency. KHINDIVI is the only FDA-approved oral solution formulation of hydrocortisone. It comes in a 1mg/ml strength designed to eliminate the need to split or crush tablets, and to offer simple and accurate dosing specifically tailored to each patient's needs. It does not require refrigeration, mixing, or shaking – it is a ready-to-use oral liquid solution. KHINDIVI is designed to offer administration simplicity and dosing accuracy, and to provide a therapy option for patients who have difficulty swallowing tablets or with special administration needs, such as patients with a gastric tube. Adrenocortical insufficiency is a rare, but serious condition in which the adrenal glands do not produce sufficient cortisol. Eton estimates that there are more than 5,000 adrenal insufficiency patients in the U.S. between the ages of 5 and 17, and expects peak sales of KHINDIVI, combined with ALKINDI SPRINKLE, will exceed $50 million per year. KHINDIVI will be available in the coming days in the United States exclusively through Anovo, a specialty pharmacy dedicated to serving patients with rare and chronic conditions. Anovo will administer the Eton Cares Program in partnership with Eton Pharmaceuticals. The program provides prescription fulfillment, insurance benefits investigation, educational support, financial assistance for qualified patients, and other services designed to help patients access treatment. Eton Cares will offer co-pay assistance to allow for $0 co-pays for qualifying patients.' Confident Investing Starts Here:
Yahoo
21-05-2025
- Business
- Yahoo
individual investors who own 43% along with institutions invested in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) saw increase in their holdings value last week
Significant control over Eton Pharmaceuticals by individual investors implies that the general public has more power to influence management and governance-related decisions A total of 25 investors have a majority stake in the company with 50% ownership Institutions own 34% of Eton Pharmaceuticals We check all companies for important risks. See what we found for Eton Pharmaceuticals in our free report. A look at the shareholders of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) can tell us which group is most powerful. We can see that individual investors own the lion's share in the company with 43% ownership. Put another way, the group faces the maximum upside potential (or downside risk). While individual investors were the group that reaped the most benefits after last week's 15% price gain, institutions also received a 34% cut. Let's take a closer look to see what the different types of shareholders can tell us about Eton Pharmaceuticals. See our latest analysis for Eton Pharmaceuticals Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. As you can see, institutional investors have a fair amount of stake in Eton Pharmaceuticals. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Eton Pharmaceuticals' historic earnings and revenue below, but keep in mind there's always more to the story. Our data indicates that hedge funds own 18% of Eton Pharmaceuticals. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation (and a higher share price) in the short term or medium term. Looking at our data, we can see that the largest shareholder is Opaleye Management Inc. with 11% of shares outstanding. EcoR1 Capital, LLC is the second largest shareholder owning 7.2% of common stock, and Nantahala Capital Management, LLC holds about 4.4% of the company stock. In addition, we found that Sean Brynjelsen, the CEO has 4.0% of the shares allocated to their name. A deeper look at our ownership data shows that the top 25 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority. Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too. While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves. I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions. We can report that insiders do own shares in Eton Pharmaceuticals, Inc.. It has a market capitalization of just US$525m, and insiders have US$27m worth of shares, in their own names. Some would say this shows alignment of interests between shareholders and the board. But it might be worth checking if those insiders have been selling. The general public-- including retail investors -- own 43% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. While it is well worth considering the different groups that own a company, there are other factors that are even more important. I like to dive deeper into how a company has performed in the past. You can access this interactive graph of past earnings, revenue and cash flow, for free. If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
